Wolf Popper LLP Announces Investigation on Behalf of Investors in Vanda Pharmaceuticals Inc.

Tuesday, February 12, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Feb. 12, 2019 /PRNewswire/ -- Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers

of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) securities from December 22, 2014 through February 8, 2019, who have incurred losses on their investments.

In March

2017, a qui tam whistleblower complaint was filed under seal against Vanda Pharmaceuticals, Inc. ("Vanda"). The qui tam action was unsealed on January 28, 2019. Shortly after trading began on February 11, 2019, Aurelius Value published a report entitled "Vanda: In the Land of The Blind, The One-Eyed Man is King." The report summarized the whistleblower complaint and said "Vanda has engaged in a series of fraudulent schemes, some personally orchestrated by Polymeropoulos himself, to defraud government payors. The allegations describe illegal off-label promotion of both of Vanda's drugs, Vanda's participation in a fraud involving doctors writing hundreds of "fake prescriptions" and pocketing cash using Vanda issued copay cards, falsified documents in internal systems, and resignations of senior executives who refused to participate in illegal activity."

As a result of this news, Vanda's stock price fell on Monday February 11, 2019, by $0.95 per share or 5% on heavy volume.

Vanda investors should contact Robert Finkel at (212) 759-4600 or (877) 370-7703 or at rfinkel@wolfpopper.com.

Wolf Popper has successfully recovered billions of dollars for defrauded investors.  The firm's reputation and expertise have been repeatedly recognized by the courts, which have appointed the firm to major positions in securities litigation.  See www.wolfpopper.com.

Attorney Advertising: Prior Results Do Not Guarantee A Similar Outcome.

Wolf Popper LLPRobert C. Finkel845 Third AvenueNew York, NY 10022Tel.: (212) 451-9620Tel.: (877) 370-7703Fax: (877) 370-7704Email: rfinkel@wolfpopper.com

 

Cision View original content:http://www.prnewswire.com/news-releases/wolf-popper-llp-announces-investigation-on-behalf-of-investors-in-vanda-pharmaceuticals-inc-300794056.html

SOURCE Wolf Popper LLP



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store